

Edgar Filing: ZONAGEN INC - Form 8-K

ZONAGEN INC  
Form 8-K  
July 15, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT  
(DATE OF EARLIEST EVENT REPORTED): JULY 15, 2002

ZONAGEN, INC.  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE  
(STATE OR OTHER JURISDICTION OF  
INCORPORATION OR ORGANIZATION)

0-21198  
(COMMISSION FILE NUMBER)

76-02  
(I.R.S. EMPLOYER I

2408 TIMBERLOCH PLACE, SUITE B-4  
THE WOODLANDS, TEXAS 77380  
(ADDRESS OF PRINCIPAL  
EXECUTIVE OFFICES  
AND ZIP CODE)

(281) 367-5892  
(REGISTRANT'S TELEPHONE NUMBER,  
INCLUDING AREA CODE)

ITEM 5. OTHER EVENTS

On July 15, 2002, Zonagen, Inc. issued a press release announcing that the Company and Schering-Plough Corporation have mutually agreed to terminate the worldwide licensing agreements that cover Zonagen's phentolamine based technologies for sexual dysfunction including VASOMAX(TM). The agreements had been in place since November 14, 1997. The technology was returned to Zonagen for undisclosed present and future considerations.

The press release is filed as an exhibit to this Current Report on Form 8-K and is incorporated by reference herein.

ITEM 7. EXHIBITS

Exhibit 99.1 -- Press Release dated July 15, 2002.

Edgar Filing: ZONAGEN INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZONAGEN, INC.

Date: July 15, 2002.

By: /s/ Louis Ploth, Jr.

-----  
Louis Ploth, Jr.  
Vice President, Business Development and  
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number -----	Description -----
99.1	Press Release dated July 15, 2002.